Impax Asset Management Group plc Buys 20,864 Shares of Bristol Myers Squibb Company $BMY

Impax Asset Management Group plc boosted its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 15.9% in the 2nd quarter, Holdings Channel.com reports. The firm owned 152,295 shares of the biopharmaceutical company’s stock after purchasing an additional 20,864 shares during the quarter. Impax Asset Management Group plc’s holdings in Bristol Myers Squibb were worth $7,050,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also made changes to their positions in the company. Trifecta Capital Advisors LLC acquired a new position in shares of Bristol Myers Squibb in the 2nd quarter worth approximately $25,000. REAP Financial Group LLC lifted its position in shares of Bristol Myers Squibb by 202.8% during the second quarter. REAP Financial Group LLC now owns 639 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 428 shares in the last quarter. Accent Capital Management LLC bought a new stake in Bristol Myers Squibb during the 1st quarter worth about $33,000. CBIZ Investment Advisory Services LLC boosted its stake in Bristol Myers Squibb by 66.0% in the first quarter. CBIZ Investment Advisory Services LLC now owns 581 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 231 shares during the last quarter. Finally, GKV Capital Management Co. Inc. acquired a new stake in shares of Bristol Myers Squibb during the first quarter worth $36,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Insiders Place Their Bets

In related news, EVP David V. Elkins sold 56,000 shares of the business’s stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the sale, the executive vice president owned 167,379 shares in the company, valued at $7,922,048.07. The trade was a 25.07% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.09% of the stock is owned by corporate insiders.

Bristol Myers Squibb Stock Down 0.9%

Shares of NYSE BMY opened at $48.64 on Friday. The company has a market cap of $99.02 billion, a price-to-earnings ratio of 19.61, a PEG ratio of 2.23 and a beta of 0.33. The company has a current ratio of 1.21, a quick ratio of 1.11 and a debt-to-equity ratio of 2.54. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $63.33. The stock has a 50-day moving average price of $45.35 and a two-hundred day moving average price of $46.71.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.52 by $0.11. The company had revenue of $12.22 billion for the quarter, compared to analyst estimates of $11.75 billion. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The firm’s revenue was up 2.8% on a year-over-year basis. During the same period in the previous year, the firm posted $1.80 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. As a group, analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, November 3rd. Stockholders of record on Friday, October 3rd were paid a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.1%. The ex-dividend date was Friday, October 3rd. Bristol Myers Squibb’s dividend payout ratio is presently 83.78%.

Analysts Set New Price Targets

A number of analysts recently weighed in on BMY shares. Daiwa America downgraded shares of Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 5th. Daiwa Capital Markets cut Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 target price for the company. in a research note on Tuesday, August 5th. Scotiabank started coverage on shares of Bristol Myers Squibb in a research note on Thursday. They set a “sector perform” rating and a $45.00 price objective for the company. Sanford C. Bernstein reissued a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, November 3rd. Finally, Dbs Bank raised shares of Bristol Myers Squibb to a “moderate buy” rating in a report on Thursday, October 2nd. Four analysts have rated the stock with a Buy rating and fifteen have given a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $54.58.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.